Ilse-Gerlinde Sunk, M.D.

Ilse-Gerlinde Sunk, M.D.


New OA Therapy Could Halt Cartilage Destruction
Ilse-Gerlinde Sunk, M.D.

Harvard School of Dental Medicine
Boston, MA
Effect of discoidin domain receptor 2 (DDR2) deficiency on osteoarthritis progression in a surgically induced OA mouse model

Osteoarthritis (OA), the most common rheumatic disease, is the major cause of disability in the U.S. It is critical to broaden our understanding of articular cartilage at different stages of the disease to better understand OA’s development and progression.

Recently a specific cell surface receptor, discoidin domain receptor 2 (DDR2), has been identified in cartilage cells (chondrocytes). DDR2 binds to collagen in the cartilage and releases an enzyme that causes progressive damage to joint cartilage. This mechanism may play a key role in the development and progression of OA.

Dr. Sunk’s project aims to verify the role of DDR2 in an animal model of OA. Blocking DDR2 may give us opportunities of intervention that will slow down or even halt cartilage destruction. If effective, this will maximize the quality of life and independence for the increasing number of people with OA.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.